Abstract

OBJECTIVE:To explore the expression of Survivin gene inhibiting apoptosis in the tissue of cardiac cancer and its correlation with clinicopathological features. METHODS: Two-step immunohistochemistry technology (Envision) was adopted to detect the expression of Survivin gene in 66 cases of cardiac cancer, and the relationship between the expression and clinicopathological features of cardiac cancer was investigated. RESULTS: In cancer tissue and tissues surrounding cancer, the positive expression rates of Survivin were 62.1% (41/66) and 24.2% (16/66) respectively,no Survivin expression was found in normal gastric mucosa, and the positive rates among these three groups had a statistical difference,P0.05. Survivin protein positive expression in low differentiation gastric cardiac carcinoma was 73.8% (31/42), and compared with high and moderate differentiation carcinoma positive rate 41.7% (10/24) there was a statistical difference,χ~2=5.409 4,P0.05. Surrivin protein positive expression rate was 73.3% (33/45) in those patients with lymph node metastasis,while only 38.1% (8/21) in those patients without lymph node metastasis, and a statistical difference was found, χ~2=6.132 4,P0.05. Positive Survivin expression rate was 74.4% in those patients with serosal infiltration while only 44.4% (12/27) in those patients without serosal infiltration,also there was a significant difference between them, χ~2=4.862 8,P0.05. TNM classification stage Ⅲ gastric cardiac carcinoma’s positive Survivin expression rate was 95% (19/20) and it was significantly higher than that of stage Ⅰ and Ⅱ, 47.8% (22/46), χ~2=11.254 4,P0.05. The expression of Survivin gene had a positive correlation with gastric cardiac carcinoma differentiation, clinical staging and lymph node metastasis, but it had no correlation with ages, sex and tumor size of cardiac carcinoma. CONCLUSIONS: Survivina inhibitor of apoptosis may correlate with the carcinogenesis and progression of cardiac carcinoma. The detection of Survivin can be worthwhile to judge the malignance and progression of cardiac cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call